IGEA Pharma has announced that LMH – an industrial holding company – has completed the due diligence process for a euro 6.000.000 committment to fund the swiss CBD extraction facility

Hoofddorp, the Netherlands, 13th July 2022. Today IGEA Pharma N.V. (SIX: IGPH) has announced that LMH Holding has completed the due diligence process on the Company in relation to its Euro 6.0 million commitment to fund the GMP-Pharma CBD extraction facility owned through its joint-venture Blue Sky Swisse S.A.

Read More

IGEA pharma non-executive board members resigned after completion of the first post-combination phase. New members to be nominated

Hoofddorp, the Netherlands, 1February 2022. Today the Board of Directors of IGEA Pharma N.V. (SIX: IGPH) has acknowledged the resignation of Mrs Giovanna Puppo, Mr Raffaele Bertoni, Mr Lieven Baten and Mr Massimiliano Colella as members of the Board of Directors. The resignation is effective as of 31 January 2022 and is motivated by personal reasons.

Read More

IGEA has been granted the listing of the new shares from SIX Exchange Regulation.

Hoofddorp, the Netherlands, 27September 2021. IGEA Pharma N.V. (SIX: IGPH) today announced that SIX Exchange Regulation AG (“SIX”) has granted the listing of 307’700’514 new registered shares with a nominal value of EUR 0.01 each out of authorized capital of IGEA Pharma NV, according to the International Reporting Standard of SIX Swiss Exchange.

Read More

IGEA to submit the listing prospectus to the SIX following the business combination with Blue Sky Natural Resources

Hoofddorp, the Netherlands, 06Septmeber 2021. IGEA Pharma N.V. (SIX: IGPH) today announced the application of the listing prospectus to the SIX Swiss Exchange Ltd (“SIX”) for the admission of the New IGEA Pharma Shares to trading. The New Shares to be listed in accordance with the International Reporting Standard of SIX will be exclusively issued to current shareholders of Blue Sky Natural Resources Ltd.

Read More